Jun 22, 2018 9:00am EDT Processa Pharmaceuticals Receives Orphan Designation Status For PCS499 In Necrobiosis Lipoidica From The Food And Drug Administration (FDA)
Mar 21, 2018 9:00am EDT Processa Pharmaceuticals Announces That It Has Been Assigned The License For The Clinical Stage Compound CTP-499 And Plans To Develop The Drug In Multiple Unmet Medical Need Conditions
Dec 11, 2017 9:03am EST Processa Pharmaceuticals Announces Reverse Stock Split and Launches New Website
